Drug Profile
Metazosin - Zentiva
Alternative Names: Kenosin; VUFB 15111Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator VUFB
- Class Amines; Antiglaucomas; Antihypertensives; Heart failure therapies; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypertension
- Discontinued Acute heart failure; Benign prostatic hyperplasia; Glaucoma
Most Recent Events
- 22 Jan 2018 Discontinued - Phase-III for Acute heart failure in Czech Republic (IV) (Zentiva website, January 2018)
- 15 Sep 2003 Leciva has merged with Slovakofarma to form Zentiva
- 13 Feb 2001 Metazosin is available for licensing